See your body's natural response to COVID-19
COVID-19 Antibody Testing by chemiluminescence (CLIA) or ELISA
Testing is for isotype-specific IgG, IgM and IgA COVID-19 spike protein and nucleocapsid antibodies
Positive result indicates an individual has mounted an immune response against the virus or in response to vaccination, and is protected against severe course of infection or reinfection
A positive antibody result may exempt employees from future testing
Specimens are collected by blood draw
The cash price for this test is $125
Includes laboratory testing and specimen collection fees
Testing may be covered by private insurance, Medicaid, Medicare and other governmental reimbursers.
For more information on KSL Diagnostics test pricing and policies, see below or call 1-800-960-1080 to speak with a representative.
Click or tap here to view technical details of this test.
Frequently Asked Questions
Why do I need a COVID-19 antibody test?
- With the recent FDA approval of vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19), testing that quantitatively measures the production of these specific antibodies toward COVID-19 has become clinically valuable in the evaluation of vaccine response. The recently approved mRNA vaccines induce antibody response against the SARS-CoV-2 spike protein. Spike protein antibodies demonstrate potent antiviral activity and correlate with potential immunity. Antibodies against the virus after a natural COVID-19 infection are present; however, these significantly decrease over time. The duration of antibody protection varies from person-to-person. Likewise, antibody levels can determine protection from COVID-19 infection post-vaccination. The presence of antibodies in both cases may indicate protection against severe course of infection or reinfection.
What makes KSL's antibody testing special?
KSL offers a NYSDOH-approved test for measurement of antibodies to spike and nucleocapsid proteins. Recognizing the need for tests to determine immune response post-infection or post-vaccination, KSL has designed and developed its highly accurate, isotype-specific IgG, IgM and IgA chemiluminescence immunoassays against the COVID-19 spike and nucleocapsid proteins—effectively detecting and differentiating between post-infection and vaccine-mediated antibody response (including Pfizer and Moderna vaccines).
Many COVID-19 antibody tests are not valid for testing vaccine effectiveness due to targeting the wrong proteins or suffering from poor sensitivity and specificity. KSL’s COVID-19 antibody test provides a peace of mind, detecting an immune response in both vaccinated and previously COVID-19 infected individuals.
What are COVID-19 antibodies?
Antibodies are one way an individual’s immune system fights infections. People with a healthy immune system develop antibodies against COVID-19 virus shortly after infection. These antibodies are detectable by laboratory tests after about one week after initial infection. In most people, the antibodies clear the COVID-19 infection after about two weeks. While the antibodies are detectable later than the virus, they may help establish the initial diagnosis of a symptomatic patient and offer additional benefits such as:
- Antibodies indicate an individual’s resistance to the virus and reinfection. If the virus is no longer detectable, these people present a minimal risk of spreading the virus.
- Contact tracing. Antibodies persist after an infection is resolved, so COVID-19 antibodies can help individuals and health care practitioners trace back to the source of the COVID-19 and identify individuals that may have been exposed to the infection in the past
What is a chemiluminescence immunoassay (CLIA)?
- An immunoassay is a test that measures biomarkers through binding with antibodies and/or antigens. Chemiluminescence allows these reactions to be detected through emission of light. The KSL COVID-19 antibody tests utilize a high throughput chemiluminescence immunoassay (CLIA) instrument to detect these antibodies.
What can my COVID-19 test results tell me?
- Consult this table for basic interpretation of results. This is a guide. Please consult your healthcare provider assistance with your diagnosis and more detailed information.
How much does the test cost and who pays for it?
The cost for COVID-19 Virus Testing by RT-PCR (CPT Code U0004) or COVID-19 IgG, IgM, IgA Antibody Testing by CLIA (CPT Codes 86769 x3) is $100 per test, plus $25 for specimen collection ($125 total for each test). Learn more about RT-PCR virus testing here. Testing may be covered by private insurance, Medicaid, Medicare and other governmental reimbursers. If you have specific questions, please call KSL at 1-800-960-1080 to speak with a representative.
Does insurance cover this test?
- Insurance will generally only cover testing for patients with suspected COVID-19 exposure and symptoms consistent with COVID-19. For all other COVID-19 testing needs—including travel, pre-operative, and elective COVID-19 testing—please contact your insurance company.
Are these tests approved by FDA?
- The COVID-19 tests currently offered by KSL are approved by FDA through Emergency Use Authorization (EUA).
How can I be tested?
- KSL offers local specimen draws and specimen collection kits for physicians and health care providers throughout the US. Kits may be ordered by calling 1-800-960-1080 or completing a request on the website.